Key facts
- Kihealth launched its beta Intercept™ test.
- The test is designed for real-time detection and monitoring of diabetes and metabolic diseases.
- It utilizes a next-generation cfDNA assay.
- The assay is built on the Kihealth InterceptIQ™ platform.
Kihealth, Inc. has announced the launch of its beta Intercept™ test. This next-generation cfDNA assay is built on the Kihealth InterceptIQ™ platform and aims to advance the real-time detection of diabetes. The technology holds potential for earlier detection, dynamic disease monitoring, and precision therapeutic development in the fields of diabetes and metabolic disease. The announcement was made on June 5, 2026, from St. Augustine, Florida.